Skip to main content
Erschienen in: Arthritis Research & Therapy 1/2017

Open Access 01.12.2017 | Erratum

Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis

verfasst von: Jérémie Sellam, Elodie Rivière, Alice Courties, Paul-Olivier Rouzaire, Barbara Tolusso, Edward M. Vital, Paul Emery, Gianfranco Ferraccioli, Martin Soubrier, Bineta Ly, Houria Hendel Chavez, Yassine Taoufik, Maxime Dougados, Xavier Mariette

Erschienen in: Arthritis Research & Therapy | Ausgabe 1/2017

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The online version of the original article can be found under doi:10.​1186/​s13075-016-1190-z.

Erratum

Unfortunately, after publication of this article [1], it was noticed that the name of Gianfranco Ferraccioli was incorrectly spelled as Gianfranco Ferraciolli. The corrected author list can be seen above and the original article has been updated to correct this error.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
download
DOWNLOAD
print
DRUCKEN
Literatur
1.
Zurück zum Zitat Sellam J, Rivière E, Courties A, Rouzaire PO, Tolusso B, Vital EM, Emery P, Ferraccioli G, Soubrier M, Ly B, Hendel Chavez H, Taoufik Y, Dougados M, Mariette X. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Res Ther. 2016;18:294. http://doi.org/10.1186/s13075-016-1190-z.CrossRefPubMedPubMedCentral Sellam J, Rivière E, Courties A, Rouzaire PO, Tolusso B, Vital EM, Emery P, Ferraccioli G, Soubrier M, Ly B, Hendel Chavez H, Taoufik Y, Dougados M, Mariette X. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Res Ther. 2016;18:294. http://​doi.​org/​10.​1186/​s13075-016-1190-z.CrossRefPubMedPubMedCentral
Metadaten
Titel
Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
verfasst von
Jérémie Sellam
Elodie Rivière
Alice Courties
Paul-Olivier Rouzaire
Barbara Tolusso
Edward M. Vital
Paul Emery
Gianfranco Ferraccioli
Martin Soubrier
Bineta Ly
Houria Hendel Chavez
Yassine Taoufik
Maxime Dougados
Xavier Mariette
Publikationsdatum
01.12.2017
Verlag
BioMed Central
Erschienen in
Arthritis Research & Therapy / Ausgabe 1/2017
Elektronische ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-017-1221-4

Weitere Artikel der Ausgabe 1/2017

Arthritis Research & Therapy 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.